Layoffs
Spero is reducing a huge chunk of its staff to minimize expenses and reallocate resources toward more promising projects in anticipation of the FDA’s decision on its NDA for tebipenem HBr.
Genocea Biosciences and Solid Biosciences are undertaking a new strategic prioritization that includes reducing their headcount.
Sio Gene has terminated its licensing deal with the UMass to develop and commercialize two gene therapy product candidates to focus on more potentially profitable projects.
Novartis, Nektar and BridgeBio confirm their plans to restructure their operation, including a number of their employees being laid off.
Nektar Therapeutics outlined a strategic reorganization plan that includes cutting 70% of its workforce. This comes only weeks after BMS abandoned its clinical collaboration program with Nektar.
The first quarter hasn’t been kind to international biopharmaceutical firms. BioSpace takes a look at the fates of Saniona and Black Diamond below.
Finch Therapeutics has slashed its headcount by 20% in order to free funds to focus its resources on its programs in recurrent C. difficile infection and autism spectrum disorder
Weeks after Imara announced its plans to discontinue the development of tovinontrinein for sickle cell and beta-thalassemia and heart failure, the company has culled 83% of its workforce.
The revised operating plan also includes reductions in spending related to general and administrative expenses and investments in its research platform.
ProQR Therapeutics, which is developing RNA therapies for genetic eye diseases, announced Wednesday that it will be restructuring and laying off 30% of its staff.
PRESS RELEASES
